Suchergebnisse - Yingzi Zhen

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China von Guoqing Liu, Kun Huang, Gang Li, Yingzi Zhen, Zhengping Li, Zhenping Chen, Runhui Wu

Connect to this object online.

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A von Di Ai, Kun Huang, Gang Li, Yingzi Zhen, Xinyi Wu, Ningning Zhang, Aihua Huo, Zhenping Chen, Runhui Wu

Connect to this object online.

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A von Zhenping Chen, Kun Huang, Gang Li, Yingzi Zhen, Xinyi Wu, Ai Di, Guoqing Liu, Zekun Li, Iorio Alfonso, Runhui Wu

Connect to this object online.

Low‐dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor‐titer below 200 BU/mL von Zhengping Li, Jie Sun, Zekun Li, Zhenping Chen, Guoqing Liu, Wanru Yao, Xiaoling Cheng, Gang Li, Yingzi Zhen, Di Ai, Yaohan Zhou, Qianqian Mao, Man‐Chiu Poon, Runhui Wu

Connect to this object online.